

WORKSHEET: Regulatory Review			
DOC#	REV DATE	PAGE	
HRP-420	08/27/2025	1 of 2	

This worksheet is used when <Regulatory Reviewers> conduct <Regulatory Review>

Check all items that apply				
1.		IRBNet #:		
1.1	☐ Regulated by:			
	☐ DHS-Department of Homeland Security	☐ HHS-Department of Health and Human Services (via FWA)		
	☐ DOD-Department of Defense	☐ HHS-Department of Health and Human Services (via		
1.2		funding		
	☐ ED-Department of Education	☐ Other Common Rule Agency		
	☐ FDA-Food and Drug Administration	☐ <2018 Requirements>		
1.3	☐ Requires compliance with ICH-GCP			
1.4	☐ Additional local, state, or international laws apply.			
2.				
2.1	☐ Waiver of Consent HHS (HRP-300)			
2.2	☐ Waiver of Consent Emergency Research (HRP-301)			
2.3	☐ Waiver of Documentation of Consent (HRP-303)			
2.4	☐ Pregnant Women (HRP-305)			
2.5	☐ Neonates of Uncertain Viability (HRP-306)			
2.6	□ Nonviable Neonates (HRP-307)			
2.7	☐ Prisoners (HRP-308)			
2.8	☐ Unexpected Incarceration (HRP-309)			
2.9	☐ Children (HRP 310)			
2.10	☐ Wards (HRP-311)			
2.11	☐ Scientific and Scholarly Review (HRP-401)			
2.12	☐ Advertisements (HRP-402)			
2.13	☐ Payments (HRP-403)			
2.14	☐ Short Form (HRP-404)			
2.15	☐ Additional Criteria DOD (HRP-405)			
2.16	☐ Additional Criteria ED (HRP-407)			
2.17	☐ Additional Criteria International (HRP-410)			
2.18	☐ Adults Lacking Capacity (HRP-414)			
3.	Drugs			
3.1	$\hfill\Box$ Evaluate all drugs whose use is specified by the protocol (See "	WORKSHEET: Drugs (HRP-425)" for definition of drug)		
3.2	☐ For approved drugs ensure that a package insert is available to	IRB members		
3.3	☐ Determine IND status and contingencies (See "WORKSHEET: I	Drugs (HRP-425)")		
3.4	☐ Procedures to control IND drugs are adequate to prevent use in individuals who are not subjects			
3.5	☐ Procedures are in place to comply with sponsor requirements w	hen an investigator holds the IND		



WORKSHEET:	Regulatory Rev	/iew
DOC#	REV DATE	PAGE
HRP-420	08/27/2025	2 of 2

4.	Devices			
4.1	☐ Evaluate all devices being evaluated for safety or effectiveness (See "CHECKLIST: Devices (HRP-326)" for definition of device)			
4.2	☐ Ensure that a PMA, 510(k), HDE approval or copy of Class I exemption category for approved devices is available to IRB			
	members			
4.3	☐ Determine IDE status and contingencies (See CHECKLIST: Devices (HRP-326)")			
4.4	☐ Procedures to control IDE devices are adequate to prevent use in individuals who are not subjects			
4.5	☐ Procedures are in place to comply with sponsor requirements when an investigator holds the IDE			
5. Check				
5.1	☐ The [Organization's] policy allows the research			
5.2	☐ The submission is complete			
5.3	☐ Investigators and research staff are up to date on training			
5.4	☐ Site agreements are in place			
5.5	☐ Investigator agreements are in place			
5.6	☐ FWA is present for federally funded research			
5.7	☐ An agency-specific assurance or assurance addendum is present when required (e.g., DOD)			
5.8	☐ Financial declarations have been made			
5.9	☐ A management plan is in place for any positive financial declaration			
5.10	☐ The [Organization] has no financial interest in the research			
5.11	☐ The description of <legally authorized="" representative=""> is consistent with laws of the jurisdiction in which the research is</legally>			
	conducted			
5.12	☐ The description of <children> is consistent with laws of the jurisdiction in which the research is conducted</children>			
5.13	☐ The description of <guardians> is consistent with laws of the jurisdiction in which the research is conducted</guardians>			
5.14	☐ HIPAA authorization requirements are not needed or are met (See "WORKSHEET: HIPAA Authorization (HRP-427)")			
5.15	☐ HIPAA wavier of authorization requirements are not needed or are met (See "WORKSHEET: HIPAA Waiver of Authorization			
	(HRP-428)")			
5.16	☐ Certifications/attestations for translated documents are present or are not needed			
6.	Notes			